Both PTEN loss and epidermal growth factor receptor (EGFR) amplification have shown significant prediction of radiorecurrence in prostate cancer,19,22 as has cyclooxygenase 2 (COX2),11 which has a pro-inflammatory function. Here, PTGS2 is linked to prostate cancer.